Quarterly report · Q2
3762.TEDINET S100SAO3
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.6bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥13.1bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥46.0bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥20.7bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥10.9bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.4bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.0bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.4bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥851m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥561m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥949m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥682m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥72.5bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥65.7bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥60.8bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥47.5bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥41.8bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥25.0bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥23.9bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥21.8bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥20.2bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥20.1bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥19.0bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥17.4bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥22.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥20.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥18.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥2.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.3bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥654m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥996m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥1.3bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥319m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥35.28 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥21.21 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥73.91 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥26.65 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥14.06 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥35.16 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥21.14 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥73.67 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥26.57 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥14.02 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 27.7% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.9% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.6% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥218m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥218m |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥122m |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥86m |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥16.5bn |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥16.4bn |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥95m |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E05463-000Medical System Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E05463-000Medical System Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E05463-000Medical System Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥498m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥24.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥24.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥218m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥175m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥175m |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥65m |
| jpcrp040300-q2r_E05463-000Application Servicereportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥81m |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.5bn |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥108m |
| jpcrp040300-q2r_E05463-000Information Infrastructurereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E05463-000Medical System Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E05463-000Medical System Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E05463-000Medical System Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E05463-000Medical System Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥748m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥20.9bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥20.7bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥175m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥1.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 878
| Item | Context | Value | Unit |
|---|---|---|---|
| Other fin cf IFRS | Prior1YTDDuration | -7881000 | JPY |
| Other fin cf IFRS | CurrentYTDDuration | -3221000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -319242000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | 996454000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 1530000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 25207000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | 1060703000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | 2809290000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 18155903000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 20071540000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 19216606000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 22880831000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000InformationInfrastructureReportableSegmentMember | 13366246000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000ApplicationServiceReportableSegmentMember | 3364128000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000MedicalSystemBusinessReportableSegmentMember | 4013479000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 20743854000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | - | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 20743854000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000InformationInfrastructureReportableSegmentMember | 107956000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000ApplicationServiceReportableSegmentMember | 64964000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000MedicalSystemBusinessReportableSegmentMember | 2336000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 175257000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -175257000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration | - | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000InformationInfrastructureReportableSegmentMember | 13474202000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000ApplicationServiceReportableSegmentMember | 3429093000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000MedicalSystemBusinessReportableSegmentMember | 4015815000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 20919111000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -175257000 | JPY |
| Revenue IFRS | Prior1YTDDuration | 20743854000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000InformationInfrastructureReportableSegmentMember | 1248321000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000ApplicationServiceReportableSegmentMember | -80733000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05463-000MedicalSystemBusinessReportableSegmentMember | 748001000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1915588000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | - | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 1915588000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 41150000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 37219000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | -4996000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 1914523000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05463-000InformationInfrastructureReportableSegmentMember | 16370874000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05463-000ApplicationServiceReportableSegmentMember | 3873132000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05463-000MedicalSystemBusinessReportableSegmentMember | 4358644000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 24602651000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 24602651000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05463-000InformationInfrastructureReportableSegmentMember | 95435000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05463-000ApplicationServiceReportableSegmentMember | 122104000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05463-000MedicalSystemBusinessReportableSegmentMember | - | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 217540000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |